The groundbreaking clinical trial assessing the effectiveness of the SGLT2 inhibitor EMPA in preventing Cardiovascular Disease in people with diabetes is the Empagliflozin Cardiovascular Outcome Event Trial in type 2 diabetes Mellitus Patients–Removing Excess Glucose (EMPA-REG) [25,51]. The gene discussed is SLC5A2; the disease is cardiovascular disorder.